KUALA LUMPUR, May 28 (Bernama) -- The Montreal Heart Institute (MHI) has announced that the COLCORONA study results have been published in The Lancet Respiratory Medicine.
The article is entitled, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
Based on a statement, Colchicine is an inexpensive and readily available anti-inflammatory drug. Orally administered, it is currently prescribed to treat gout, Familial Mediterranean Fever and pericarditis.
It has concluded that, given the lack of oral therapies available to prevent COVID-19 complications among non-hospitalised patients and the observed benefit of colchicine in patients with a PCR-confirmed diagnosis of COVID-19, this anti-inflammatory drug could be considered as a treatment for those at risk of complications.
“Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19,” said Director of the MHI Research Centre, Dr Jean-Claude Tardif, who is also Professor at the Faculty of Medicine of the Université de Montréal and Principal Investigator of COLCORONA.
COLCORONA (NCT04322682) is a randomised, double-blinded, placebo-controlled, home-based clinical trial, conducted in Canada, the United States, Europe, South America and South Africa.
The study included 4,488 non-hospitalised patients over 40 years of age with COVID-19 at the time of inclusion, with at least one identified risk factor for COVID-19 complications.
Patients were randomised to receive colchicine (0.5 mg twice daily for three days and once daily after) or placebo for 30 days.
-- BERNAMA
No comments:
Post a Comment